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1 Abstract
2 Clinical trials are the gold standard for generating evidence-based knowledge in medicine; 
3 however, few are conducted in children despite this population having the highest prevalence 
4 of antimicrobial resistant (AMR) infections. Between January 2010-Dec 2019, antimicrobial 
5 clinical trials registered on clinicaltrials.gov accounted for 4·0% of all interventional clinical 
6 trials, with paediatric antibacterial clinical trials on the African continent making up <1%. 
7 The African paediatric population (particularly neonates and infants) have the highest 
8 prevalence of AMR infections, but receive the lowest investment and participation in clinical 
9 research for antibacterial agents. African clinician investigators, who are most familiar with 
10 the local disease burden and health system challenges, are best suited to lead research efforts 
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27 Clinical trials are the gold standard for generating evidence-based knowledge in medicine. A 
28 disproportionately small number of clinical trials are conducted in children, a unique 
29 population who require age- and development-specific treatments. The rise in prevalence of 
30 antimicrobial resistant (AMR) – specifically antibacterial resistant – paediatric infections in 
31 both community and hospital settings in Africa [1, 2] has not been matched by increases in 
32 access to effective antimicrobial therapy. In many low-resource settings, empirical 
33 antimicrobial therapies are no longer effective, and therapeutic options for AMR pathogens 
34 are either unaffordable or unavailable locally. 
35
36 Given the dearth of therapeutic options for paediatric AMR infections in low-resource 
37 settings, we evaluated trends in the proportion of paediatric trials in Africa, with a specific 
38 focus on antibacterials. We reviewed all interventional clinical trials involving antibacterial 
39 agents registered on clinicaltrials.gov over a ten-year period (January 2010-Dec 2019), in 
40 children up to 17 years of age. We excluded studies of antimicrobial prophylaxis, non-
41 systemic, non-antibacterial, and antimycobacterial agents, and trials of unknown status or 
42 withdrawn before enrollment. Each site country in multi-site antibacterial trials was 
43 considered a unique study. Full names were used to approximate the investigator genders. 
44 The overall principal investigator was determined for multi-site studies and a study was 
45 considered to be African-led if any overall principal investigator was from an African 
46 institution.  
47
48 We identified 224,297 studies, of which 141,118 (62·.9%) were interventional clinical trials. 
49 Antimicrobial clinical trials accounted for 4·.0% (5,600/141,118), with paediatric 
50 involvement in 0·.8% of interventional trials (1,121/141,118). Less than 10% (111/1,121) of 
51 paediatric antimicrobial clinical trials were/are being conducted in Africa. Of these, 104 
52 (93·.7%) had a sponsor and/or principal investigator from outside the African continent. We 
Page 2 of 8
URL: https://mc.manuscriptcentral.com/eri   Email: IERZ-peerreview@journals.tandf.co.uk





























































For Peer Review Only
3
53 classified 47 46 as antibacterial trials in Africa, of which seven were African-led (15%) and 
54 four of those (57%) had a female principal investigator.  
55
56 Between 2010-2014 and 2015-2019, the number of registered studies increased 32·.9%, 
57 interventional clinical trials increased 50·.1%, and paediatric interventional clinical trials 
58 increased 47·.7% (Figure 1A). By comparison, paediatric interventional antimicrobial clinical 
59 trials increased 25·.6% over this same period (Figure 1B). The most common infectious 
60 conditions evaluated were trachoma, malnutrition, diarrhoea and pneumonia. The most 
61 common antibacterial classes involved were macrolides (azithromycin, 19/46 (41%)), and 
62 penicillins (amoxicillin, 11/46 (24%)).  Although in Africa the number of paediatric 
63 interventional antibacterial clinical trials roughly doubled during this timeframe, the 47 46 
64 trials that were conducted over a 10-year period equates to 0·.8% of all interventional 
65 antimicrobial clinical trials registered. 
66
67 These data highlight several issues: firstly, though the number of clinical trials conducted 
68 globally is increasing, the number of antimicrobial clinical trials conducted in settings where 
69 burden of infectious diseases is highest remains disproportionately low. This may reflect the 
70 lack of discovery of new antibiotic classes in the last 30 years or limited capacity to conduct 
71 such trials where the burden of infectious diseases is highest. Secondly, while half of the 
72 world’s 5·.9 2 million under-five deaths occur in Africa, most attributable to infections [3, 
73 4][3, 4],[3], paediatric antibacterial clinical trials on the African continent account for <1% of 
74 all interventional clinical trials. Thirdly, whereas 44% of all child deaths now occur in the 
75 neonatal period,[4] [5], only two antibacterial clinical trials were specifically designed to 
76 target neonates. Finally, non-African institutions sponsor and/or are lead investigators in the 
77 vast majority of paediatric antimicrobial clinical trials conducted in Africa. 
78
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79 Despite the history and complexity of conducting clinical trials on the continent, from basic 
80 infrastructure to questionable ethical practices,[5-7] [6-8], the foundation for clinical trials in 
81 Africa has improved immensely. Capacity-building initiatives take time to bear fruit, and 
82 developing research infrastructure is a long-term investment. African-led clinician scientists 
83 are best placed to ask relevant research questions in their local setting, and should be 
84 supported and empowered to conceive, design, and lead studies to answer the research 
85 questions derived from their settings.[8] [9]. This would identify context-based solutions 
86 adaptable to different parts of the continent.
87
88 This study has several limitations. Firstly, we only reviewed clinical trials registered on 
89 clinicaltrials.gov, which would have missed non-listed research and protocols registered only 
90 on local/national regulatory websites. Secondly, though an antibacterial trial may have 
91 involved multiple countries, each country involved was counted as a unique study. If 
92 anything, this approach would have led to an overestimation of the representation of African 
93 antibacterial clinical trials in the global context. 
94
95 AMR is a growing public health crisis disproportionately affecting African countries where 
96 infection burden is high but access to effective therapies is severely limited. The African 
97 paediatric population (particularly neonates and infants) have the highest prevalence of AMR 
98 infections, but receive the lowest investment and participation in clinical research for 
99 antibacterial agents. We argue that African clinician investigators, who are most familiar with 
100 the local disease burden and health system challenges, are best suited to lead research efforts 




Page 4 of 8
URL: https://mc.manuscriptcentral.com/eri   Email: IERZ-peerreview@journals.tandf.co.uk



































































109 Figure 1. Number of A) Registered clinical trials globally; B) Paediatric clinical trials in 
110 Africa
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